Living a full life with Chronic Obstructive Pulmonary Disease (COPD) is more accessible than ever before with today’s online resources. Whether you’re looking for in-depth tutorials, facts, or simple tips on self-management, the web offers information at your fingertips. Here’s a few of our favourite bookmark-worthy websites for you!
Post-operative pulmonary complications (PPCs) are a major burden to the healthcare system. A new real-world study published in Pulmonary Therapy, indicates significant reductions in costs when using the Aerobika* oscillating positive expiratory pressure (OPEP) device in the postoperative care setting.1
Trudell Medical UK Ltd (TM-UK) is now the UK distributor for the full AeroChamber Plus* range of Valved Holding Chambers (VHCs)
Poster presented at DDL 2017 in Edinburgh.
Aerobika* device proves to be a cost-effective treatment option in the management of post-exacerbation COPD patients.
Did you know that cold air can worsen your Chronic Obstructive Pulmonary Disease (COPD) symptoms?
When cold air (especially cold, dry air) enters the lungs it can cause the airways to constrict, resulting in shortness of breath and flare-ups of COPD symptoms. The good news is that these effects can be avoided by checking the weather forecast and planning ahead. If you need to go out into the cold weather, here are some tips that may help.
New information regarding the efficiency and effectiveness of different oscillating positive expiratory pressure devices was presented at CHEST 2017 in Toronto, Canada.
Treatment with the Aerobika* device can significantly reduce the recurrence of exacerbations of COPD in the crucial 30-day period following hospitalization or emergency room visits, according to a study published this month in Pulmonary Therapy.
Oscillating positive expiratory pressure (OPEP) devices may reduce chronic symptoms in patients with obstructive pulmonary disease (COPD); however, no real-world studies have been performed to evaluate the benefits of these devices. The objective of this study was to measure the rate of early (30-day) moderate-to-severe exacerbations and related costs in COPD patients treated with Aerobika*, an OPEP device, vs. a matched control group in a real-world setting.
A recent study by Western University researchers, published in the Journal of Chronic Obstructive Pulmonary Disease, reveals that the use of the Aerobika® device, has a significant impact on quality of life for study patients suffering from chronic bronchitis, a disease that accounts for almost 70% of Chronic Obstructive Pulmonary Disease (COPD) diagnoses globally. These study results show significan